TransCode Therapeutics (NASDAQ: RNAZ) announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in up to 45 colorectal cancer patients who remain circulating tumor DNA-positive following curative-intent therapy despite no radiographic evidence of disease, indicating minimal residual disease. The trial is conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform, and will assess the biological and clinical activity of TTX-MC138 in reducing recurrence risk in this high-risk patient population.
This announcement is significant because it addresses a critical unmet need in colorectal cancer management. Patients with minimal residual disease, as detected by circulating tumor DNA, are at high risk of recurrence even after successful primary treatment. TTX-MC138 targets microRNA-10b, a biomarker of metastasis, and could potentially prevent or delay disease progression. The use of the PRE-I-SPY platform, which is designed for efficient and adaptive trial designs, may accelerate the development process and provide earlier insights into the drug's efficacy.
TransCode Therapeutics is a clinical stage company pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
For more information about TransCode Therapeutics and its latest news, visit the company's newsroom at https://ibn.fm/RNAZ. The full press release is available at https://ibn.fm/wuRri.
The initiation of this Phase 2a trial marks a step forward in potentially improving outcomes for colorectal cancer patients with minimal residual disease. If successful, TTX-MC138 could become an important therapeutic option for reducing recurrence risk and improving survival in this patient population.
